287 related articles for article (PubMed ID: 18783201)
1. Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potency and in vivo efficacy and safety.
Connolly BA; Sanford DG; Chiluwal AK; Healey SE; Peters DE; Dimare MT; Wu W; Liu Y; Maw H; Zhou Y; Li Y; Jin Z; Sudmeier JL; Lai JH; Bachovchin WW
J Med Chem; 2008 Oct; 51(19):6005-13. PubMed ID: 18783201
[TBL] [Abstract][Full Text] [Related]
2. 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity.
Yamazaki K; Yasuda N; Inoue T; Nagakura T; Kira K; Shinoda M; Saeki T; Tanaka I
J Pharmacol Exp Ther; 2006 Dec; 319(3):1253-7. PubMed ID: 16980568
[TBL] [Abstract][Full Text] [Related]
3. 2-[3-[2-[(2S)-2-Cyano-1-pyrrolidinyl]-2-oxoethylamino]-3-methyl-1-oxobutyl]- 1,2,3,4-tetrahydroisoquinoline: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV.
Tsu H; Chen X; Chen CT; Lee SJ; Chang CN; Kao KH; Coumar MS; Yeh YT; Chien CH; Wang HS; Lin KT; Chang YY; Wu SH; Chen YS; Lu IL; Wu SY; Tsai TY; Chen WC; Hsieh HP; Chao YS; Jiaang WT
J Med Chem; 2006 Jan; 49(1):373-80. PubMed ID: 16392822
[TBL] [Abstract][Full Text] [Related]
4. 4-Substituted boro-proline dipeptides: synthesis, characterization, and dipeptidyl peptidase IV, 8, and 9 activities.
Wu W; Liu Y; Milo LJ; Shu Y; Zhao P; Li Y; Woznica I; Yu G; Sanford DG; Zhou Y; Poplawski SE; Connolly BA; Sudmeier JL; Bachovchin WW; Lai JH
Bioorg Med Chem Lett; 2012 Sep; 22(17):5536-40. PubMed ID: 22853995
[TBL] [Abstract][Full Text] [Related]
5. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.
Kirby M; Yu DM; O'Connor S; Gorrell MD
Clin Sci (Lond); 2009 Sep; 118(1):31-41. PubMed ID: 19780719
[TBL] [Abstract][Full Text] [Related]
6. Pro-soft Val-boroPro: a strategy for enhancing in vivo performance of boronic acid inhibitors of serine proteases.
Poplawski SE; Lai JH; Sanford DG; Sudmeier JL; Wu W; Bachovchin WW
J Med Chem; 2011 Apr; 54(7):2022-8. PubMed ID: 21388136
[TBL] [Abstract][Full Text] [Related]
7. Dipeptide proline diphenyl phosphonates are potent, irreversible inhibitors of seprase (FAPalpha).
Gilmore BF; Lynas JF; Scott CJ; McGoohan C; Martin L; Walker B
Biochem Biophys Res Commun; 2006 Jul; 346(2):436-46. PubMed ID: 16769036
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and SAR of potent and selective dipeptide-derived inhibitors for dipeptidyl peptidases.
Senten K; Van der Veken P; De Meester I; Lambeir AM; Scharpé S; Haemers A; Augustyns K
J Med Chem; 2003 Nov; 46(23):5005-14. PubMed ID: 14584950
[TBL] [Abstract][Full Text] [Related]
9. Rational design and synthesis of potent and long-lasting glutamic acid-based dipeptidyl peptidase IV inhibitors.
Tsai TY; Hsu T; Chen CT; Cheng JH; Chiou MC; Huang CH; Tseng YJ; Yeh TK; Huang CY; Yeh KC; Huang YW; Wu SH; Wang MH; Chen X; Chao YS; Jiaang WT
Bioorg Med Chem Lett; 2009 Apr; 19(7):1908-12. PubMed ID: 19269819
[TBL] [Abstract][Full Text] [Related]
10. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Kim D; Wang L; Beconi M; Eiermann GJ; Fisher MH; He H; Hickey GJ; Kowalchick JE; Leiting B; Lyons K; Marsilio F; McCann ME; Patel RA; Petrov A; Scapin G; Patel SB; Roy RS; Wu JK; Wyvratt MJ; Zhang BB; Zhu L; Thornberry NA; Weber AE
J Med Chem; 2005 Jan; 48(1):141-51. PubMed ID: 15634008
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationships of boronic acid inhibitors of dipeptidyl peptidase IV. 1. Variation of the P2 position of Xaa-boroPro dipeptides.
Coutts SJ; Kelly TA; Snow RJ; Kennedy CA; Barton RW; Adams J; Krolikowski DA; Freeman DM; Campbell SJ; Ksiazek JF; Bachovchin WW
J Med Chem; 1996 May; 39(10):2087-94. PubMed ID: 8642568
[TBL] [Abstract][Full Text] [Related]
12. Novel trans-2-aryl-cyclopropylamine analogues as potent and selective dipeptidyl peptidase IV inhibitors.
Tsai TY; Hsu T; Chen CT; Cheng JH; Yeh TK; Chen X; Huang CY; Chang CN; Yeh KC; Hsieh SH; Chien CH; Chang YW; Huang CH; Huang YW; Huang CL; Wu SH; Wang MH; Lu CT; Chao YS; Jiaang WT
Bioorg Med Chem; 2009 Mar; 17(6):2388-99. PubMed ID: 19261480
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl peptidase IV: development, design, synthesis and biological evaluation of inhibitors.
Borloo M; De Meester I
Verh K Acad Geneeskd Belg; 1994; 56(1):57-88. PubMed ID: 7911611
[TBL] [Abstract][Full Text] [Related]
14. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Augeri DJ; Robl JA; Betebenner DA; Magnin DR; Khanna A; Robertson JG; Wang A; Simpkins LM; Taunk P; Huang Q; Han SP; Abboa-Offei B; Cap M; Xin L; Tao L; Tozzo E; Welzel GE; Egan DM; Marcinkeviciene J; Chang SY; Biller SA; Kirby MS; Parker RA; Hamann LG
J Med Chem; 2005 Jul; 48(15):5025-37. PubMed ID: 16033281
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
Lee B; Shi L; Kassel DB; Asakawa T; Takeuchi K; Christopher RJ
Eur J Pharmacol; 2008 Jul; 589(1-3):306-14. PubMed ID: 18538760
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of novel potent dipeptidyl peptidase IV inhibitors with enhanced chemical stability: interplay between the N-terminal amino acid alkyl side chain and the cyclopropyl group of alpha-aminoacyl-l-cis-4,5-methanoprolinenitrile-based inhibitors.
Magnin DR; Robl JA; Sulsky RB; Augeri DJ; Huang Y; Simpkins LM; Taunk PC; Betebenner DA; Robertson JG; Abboa-Offei BE; Wang A; Cap M; Xin L; Tao L; Sitkoff DF; Malley MF; Gougoutas JZ; Khanna A; Huang Q; Han SP; Parker RA; Hamann LG
J Med Chem; 2004 May; 47(10):2587-98. PubMed ID: 15115400
[TBL] [Abstract][Full Text] [Related]
17. Crystal structures of DPP-IV (CD26) from rat kidney exhibit flexible accommodation of peptidase-selective inhibitors.
Longenecker KL; Stewart KD; Madar DJ; Jakob CG; Fry EH; Wilk S; Lin CW; Ballaron SJ; Stashko MA; Lubben TH; Yong H; Pireh D; Pei Z; Basha F; Wiedeman PE; von Geldern TW; Trevillyan JM; Stoll VS
Biochemistry; 2006 Jun; 45(24):7474-82. PubMed ID: 16768443
[TBL] [Abstract][Full Text] [Related]
18. ASP8497 is a novel selective and competitive dipeptidyl peptidase-IV inhibitor with antihyperglycemic activity.
Matsuyama-Yokono A; Tahara A; Nakano R; Someya Y; Nagase I; Hayakawa M; Shibasaki M
Biochem Pharmacol; 2008 Jul; 76(1):98-107. PubMed ID: 18468582
[TBL] [Abstract][Full Text] [Related]
19. Potent non-nitrile dipeptidic dipeptidyl peptidase IV inhibitors.
Simpkins LM; Bolton S; Pi Z; Sutton JC; Kwon C; Zhao G; Magnin DR; Augeri DJ; Gungor T; Rotella DP; Sun Z; Liu Y; Slusarchyk WS; Marcinkeviciene J; Robertson JG; Wang A; Robl JA; Atwal KS; Zahler RL; Parker RA; Kirby MS; Hamann LG
Bioorg Med Chem Lett; 2007 Dec; 17(23):6476-80. PubMed ID: 17937986
[TBL] [Abstract][Full Text] [Related]
20. E3024, 3-but-2-ynyl-5-methyl-2-piperazin-1-yl-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one tosylate, is a novel, selective and competitive dipeptidyl peptidase-IV inhibitor.
Yasuda N; Nagakura T; Inoue T; Yamazaki K; Katsutani N; Takenaka O; Clark R; Matsuura F; Emori E; Yoshikawa S; Kira K; Ikuta H; Okada T; Saeki T; Asano O; Tanaka I
Eur J Pharmacol; 2006 Oct; 548(1-3):181-7. PubMed ID: 16973152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
